Bristol-Myers's (BMY) Inhibitex (INHX) Takeover Puts Hep-C, Other Biotechs on M&A Watch
Following Bristol-Myers Squibb's (NYSE: BMY) deal to acquire Hep C drug maker Inhibitex (Nasdaq: INHX) at a 163% premium over the weekend, speculators will be out in force in biotech-land Monday.
First and foremost, speculators will look at remaining Hep C drug developers Achillion Pharmaceuticals (Nasdaq: ACHN) and Idenix Pharmaceuticals (Nasdaq: IDIX). Bigger and more established Hep C player Vertex Pharmaceuticals (Nasdaq: VRTX) could also find itself a target.
Others biotechs said to be takeover targets include:
Alexion Pharmaceuticals (Nasdaq: ALXN), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Dendreon (Nasdaq: DNDN), Human Genome (Nasdaq: HGSI), Incyte Corporation (Nasdaq: INCY), InterMune (Nasdaq: ITMN), Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), Momenta Pharmaceuticals (Nasdaq: MNTA), Seattle Genetics (Nasdaq: SGEN) and ViroPharma Inc. (Nasdaq: VPHM).
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
First and foremost, speculators will look at remaining Hep C drug developers Achillion Pharmaceuticals (Nasdaq: ACHN) and Idenix Pharmaceuticals (Nasdaq: IDIX). Bigger and more established Hep C player Vertex Pharmaceuticals (Nasdaq: VRTX) could also find itself a target.
Others biotechs said to be takeover targets include:
Alexion Pharmaceuticals (Nasdaq: ALXN), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Dendreon (Nasdaq: DNDN), Human Genome (Nasdaq: HGSI), Incyte Corporation (Nasdaq: INCY), InterMune (Nasdaq: ITMN), Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), Momenta Pharmaceuticals (Nasdaq: MNTA), Seattle Genetics (Nasdaq: SGEN) and ViroPharma Inc. (Nasdaq: VPHM).
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Citi (C) rumored to have lost $20M on Facebook (FB) glitches -WSJ
- Facebook (FB) considering NYSE's (NYX) proposal on listing
- OmniVision (OVTI) Volatility Up on Move Lower
Create E-mail Alert Related Categories
Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
